India, Nov. 13 -- Fortress Biotech, Inc. (FBIO), a biopharmaceutical company focused on acquiring and advancing pharmaceutical assets through product revenue, equity holdings and royalty income, reported third-quarter 2026 financial results and recent corporate developments, including the full repayment of its Oaktree credit facility, the licensing of FB-607 for irritable bowel syndrome with diarrhea (IBS-D), and continued progress across its partnered programs.
Third-Quarter 2026 Financial Results
Fortress Biotech's consolidated net revenue rose approximately 9% to $19.2 million in the third quarter of 2026, up from $17.6 million in the year-ago period.
Marketed dermatology products contributed $18.9 million to quarterly revenue, compar...